The verdict
Our read at a glance.
Whether CJC-1295, ipamorelin, or combination-style claims have clinical outcome evidence beyond GH/IGF-1 biomarker movement, and whether marketed products match the studied materials.
- The signal
- CJC-1295 has small human endocrine studies showing GH/IGF-1 movement, and ipamorelin has human PK/PD plus narrow postoperative-ileus research. The wider GH-axis literature is the cautionary part: shifting those hormones is not, by itself, a proven clinical outcome.
- The unknown
- Whether any combination-style product matches studied CJC-1295 or ipamorelin materials, whether meaningful human outcomes exist for the marketed claims, and how to interpret long-term safety, cardiometabolic, cancer, and product-quality uncertainty.
- Our read
- A biomarker-heavy, outcome-light claim cluster that belongs on safety/regulatory watch until product-specific human outcomes and safety boundaries are much clearer.
The mechanism
How it works.
These are two different ways to push the same growth-hormone axis. CJC-1295-style compounds are GHRH analogs that bind the pituitary's GHRH receptor, while ipamorelin binds the ghrelin receptor as a growth-hormone secretagogue, and both make the pituitary release more growth hormone, which in turn raises IGF-1. Small studies confirm these compounds can move GH and IGF-1 in people, but moving those blood markers is not the same as a proven clinical outcome, and marketed blends may not match the materials that were actually studied.
Safety & regulatory boundary
The consequential part.
FDA identifies potential significant safety risks for compounded drugs containing CJC-1295 or ipamorelin acetate. CJC-1295 with DAC, non-DAC modified GRF, salts/free bases, ipamorelin forms, compounded products, internet-market products, and blends should not be treated as interchangeable.
What's next
What we're watching.
FDA compounding-status updates, exact-product human outcome studies, registry results, adverse-event patterns, and better separation between endocrine signal, clinical benefit, and product identity.
Context
Why this is discussed.
The claims sound measurable because GH and IGF-1 biomarkers can move, and the online pitch often connects that movement to aging, recovery, sleep, or body-composition narratives.
The evidence base
54 cited references.
Regulatory & labels12
National Library of Medicine / FDA label · Revised 2025-03
U.S. Food and Drug Administration · 2024 PCAC briefing
U.S. Food and Drug Administration · 2024 PCAC material
U.S. Food and Drug Administration · Current FDA page
U.S. Food and Drug Administration · Current FDA page
U.S. Food and Drug Administration · 2024 PCAC briefing
U.S. Food and Drug Administration · Accessed 2026-05-16
Therapeutic Goods Administration, Australia · Published 2026-03-05
Therapeutic Goods Administration, Australia · Published 2026-04-13
Medsafe New Zealand · 2015-11-24
World Anti-Doping Agency · Effective 2026-01-01
European Medicines Agency · 2017
Registered trials3
ClinicalTrials.gov / ConjuChem · NCT00267527
ClinicalTrials.gov / Helsinn Therapeutics · NCT00672074
ClinicalTrials.gov / Helsinn Therapeutics · NCT01280344
Indexed literature (PubMed)34
Teichman, Neale, Lawrence, Gagnon, Castaigne, and Frohman · 2006
Ionescu and Frohman · 2006
Sackmann-Sala, Ding, Frohman, and Kopchick · 2009
Jette et al. · 2005
Raun et al. · 1998
Gobburu et al. · 1999
Hellstrom, Beck, and the Ipamorelin 201 Study Group · 2014
Greenwood-Van Meerveld et al. · 2012
Howard et al. · 1996
Kojima et al. · 1999
Broglio et al. · 2003
Ghigo et al. · 1999
Ghigo et al. · 2001
Arvat et al. · 2001
Ahnfelt-Ronne et al. · 2001
Benso et al. · 2004
Sigalos and Pastuszak · 2018
Liu et al. · 2007
Liu et al. · 2008
Hermansen et al. · 2017
Nass et al. · 2008
Adunsky et al. · 2011
Temel et al. · 2016
Garcia et al. · 2013
Shaw et al. · 2013
Falutz et al. · 2010
Stanley et al. · 2014
Stanley et al. · 2011
Spooner and Olin · 2012
Prakash and Goa · 1999
Molitch et al. / Endocrine Society · 2011
Corneli et al. · 2007
Sponsor & other sources5
PubChem / National Center for Biotechnology Information · Current database record
National Center for Biotechnology Information · Current database record
University of Maryland M-CERSI / FDA collaboration · 2020
PubChem / National Center for Biotechnology Information · Current database record
National Center for Biotechnology Information · Current database record
Keep reading